Ibrutinib

Overview

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling, which may result to decreased growth of cancer cells.

SparkCures ID 31
Developed By Pharmacyclics
Generic Name Ibrutinib
Additional Names Imbruvica, PCI-32765
Treatment Classifications
  • Bruton's Tyrosine Kinase (BTK) Inhibitor

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.